SPR Therapeutics Announces Completion of Enrollment in the RESET Clinical Trial of the SPRINT® PNS System for Low Back Pain
CLEVELAND, Dec. 12, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. today announced the final patient was enrolled in the RESET Clinical Trial of SPRINT® PNS for the treatment of chronic low back pain (LBP).
- CLEVELAND, Dec. 12, 2023 (GLOBE NEWSWIRE) -- SPR Therapeutics, Inc. today announced the final patient was enrolled in the RESET Clinical Trial of SPRINT® PNS for the treatment of chronic low back pain (LBP).
- This large multicenter randomized controlled trial (RCT) compares percutaneous peripheral nerve stimulation (PNS) with standard interventional treatments of chronic LBP.
- The “RESET Clinical Trial: A Randomized, Controlled, Multicenter Trial of Percutaneous Peripheral Nerve Stimulation (PNS) for the Treatment of Back Pain” is a large RCT being conducted at more than 20 clinical centers across the United States.
- “We are thrilled to announce the completion of enrollment in this important study, which is the largest randomized controlled trial to date studying the SPRINT PNS System.